Seed oils are best for LDL cholesterol

If you want to lower your low-density lipoprotein cholesterol, called LDL or, colloquially, "bad cholesterol," the research is clear about one thing: You should exchange saturated fats with unsaturated fat. If you want to know what you should use to sauté your dinner, that's a harder question to answer. Many of the studies establishing that mono- and polyunsaturated fats are better for blood lipids than saturated fats swapped out one food source at a time, making it hard to tell which of a plethora of vegetable oils might be most beneficial.

Lukas Schwingshackl, a researcher at the German Institute of Human Nutrition, is among a wave of scientists using sophisticated statistical tools to reduce uncertainty about what the mountain of data in the nutrition literature can tell us. In a paper published in the Journal of Lipid Research this month, Schwingshackl and colleagues used an emerging technique called network meta-analysis to extract insight from published studies on the effect of various dietary oils on blood lipids. The researchers found that seed oils were the best choice for people looking to improve their cholesterol.

To get around the fact that there has been no giant study comparing all available oils, Schwingshackl's team constructed a network meta-analysis showing how different oils and solid fats have in fact been matched up. The researchers rounded up 55 studies dating to the 1980s that assessed the effects of consuming the same amount of calories from two or more different oils on participants' blood lipids. To be included in the analysis, a study had to compare the effect of two or more oils or fats (from a list of 13) on patients' LDL, or other blood lipids like total cholesterol, HDL-cholesterol or triglycerides, over at least three weeks.

Suppose both butter and sunflower oil had been tested against olive oil. The statistical approaches of network meta-analysis allowed the team to infer a quantitative comparison between butter and sunflower oil, even if they had never faced off in the clinic. Schwingshackl explained, "The beauty of this method is that you can compare a lot of different interventions simultaneously... and, in the end, you get a ranking. You can say, 'this is the best oil for this specific outcome.'"

In this study, the final ranking indicated that, as your doctor has been telling you for years, solid fats like butter and lard are the worst choice for LDL. The best alternatives are oils from seeds. "Sunflower oil, rapeseed oil, safflower oil and flaxseed oil performed best," said Schwingshackl. "Some people from Mediterranean countries probably are not so happy with this result, because they would prefer to see olive oil at the top. But this is not the case."

There are a few important caveats to the research. For starters, it measured only blood lipids. "This is not a hard clinical outcome," said Schwingshackl. "LDL is a causal risk factor for coronary heart disease, but it's not coronary heart disease." However, he said, it might be difficult to conduct a study comparing those clinical outcomes -- for starters, someone would need to find study participants willing to eat just one type of fat for years at a time.

Meta-analyses run the risk of misleading by combining several pieces of low-confidence data into a falsely confident-sounding ranking. In this case, for example, there was not enough evidence to choose a "winner" confidently among the seed oils. What's more, the oils best at lowering LDL were not the most beneficial for triglycerides and HDL cholesterol. However, with the appropriate caveats in mind, Schwingshackl is optimistic about the potential for network meta-analysis to help researchers synthesize disparate clinical studies in the future.

Schwingshackl L, Bogensberger B, Benčič A, Knüppel S, Boeing H, Hoffmann G.
Effects of oils and solid fats on blood lipids: a systematic review and network meta-analysis.
J Lipid Res. 2018 Sep;59(9):1771-1782. doi: 10.1194/jlr.P085522.

Most Popular Now

Walnuts may help lower blood pressure for those at…

When combined with a diet low in saturated fats, eating walnuts may help lower blood pressure in people at risk for cardiovascular disease, according to a new Penn State ...

Bristol-Myers Squibb reports first quarter financi…

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2019 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (a...

Amgen ignites a social fitness movement to support…

Amgen (NASDAQ:AMGN) launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support t...

Possible link between autism and antidepressants u…

An international team led by Duke-NUS Medical School has found a potential link between autistic-like behaviour in adult mice and exposure to a common antidepressant in t...

AstraZeneca starts artificial intelligence collabo…

AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treat...

Researchers define Alzheimer's-like brain disorder

A brain disorder that mimics symptoms of Alzheimer's disease has been defined with recommended diagnostic criteria and guidelines for advancing future research on the con...

Comprehensive tumor profiling promises new therape…

The WINTHER trial, NCT01856296, led by investigators from Vall d'Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave...

Amgen and Syapse enter precision medicine collabor…

Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, announced a precisio...

Drugs to prevent stroke and dementia show promise …

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study...

Novartis presents first-of-its-kind algorithm-base…

Novartis today announced results from a validation study of the innovative, algorithm-based digital solution MS Progression Discussion Tool, or MSProDiscussTM. The tool a...

Trastuzumab deruxtecan demonstrated clinically-mea…

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab ...

Genetic therapy heals damage caused by heart attac…

Researchers from King's College London have found that therapy that can induce heart cells to regenerate after a heart attack. Myocardial infarction, more commonly known ...